Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 18Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Follicular 10Lymphoma, Non-Hodgkin 9Lymphoma 9Lymphoma, Mantle-Cell 7Recurrence 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma, B-Cell 5Neoplasms 4Leukemia, B-Cell 2Burkitt Lymphoma 2Neoplasm, Residual 1Mature B-Cell Malignancies 1Lymphatic Diseases 1Leukemia, Hairy Cell 1Leukemia 1Heart Failure 1Dendritic Cell Sarcoma, Interdigitating 1Cytokine Release Syndrome 1

Interventions

glofitamab 2pembrolizumab 1obinutuzumab 1Oxaliplatin 1Gemcitabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dendritic Cell Sarcoma, Interdigitating × obinutuzumab × 90 days × Clear all
NCT04889716 2026-05-26

CAR-T Followed by Bispecific Antibodies

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting
23 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡